Bioventix to join AIM

Bioventix plc                                 

                        ("Bioventix" or the "Company")                         

                             Bioventix to join AIM                             

Bioventix plc (ISDX: BVXP) announces that it intends to move to AIM. It is
expected that the Company's shares will be admitted to trading on AIM on or
around 29 April 2014.

For further information please contact:

Bioventix plc                                       Tel: [phone]            
Peter Harrison           Chief Executive Officer                                
                                                                                 
finnCap Ltd                                         Tel: [phone]            
Geoff Nash/Simon Hicks   Corporate Finance          
Steve Norcross           Corporate Broking             

About Bioventix plc:

Bioventix (www.bioventix.com) specialises in the development and commercial
supply of high-affinity monoclonal antibodies with a primary focus on their
application in clinical diagnostics, such as in automated immunoassays used in
blood testing. The antibodies created at Bioventix are generated in sheep and
are of particular benefit where the target is present at low concentration and
where conventional monoclonal or polyclonal antibodies have failed to produce a
suitable reagent. Bioventix currently offers a portfolio of antibodies to
customers for both commercial use and R&D purposes, for the diagnosis or
monitoring of a broad range of conditions, including heart disease, cancer,
fertility, thyroid function and drug abuse. Bioventix currently supplies
antibody products and services to the majority of multinational clinical
diagnostics companies. Bioventix is based in Farnham, UK and its shares are
traded on ISDX under the symbol BVXP.